戊酸,5-(甲基氨基)-5-羰基- | 105611-99-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 戊酸,5-(甲基氨基)-5-羰基-
• 英文名称: Glutaric acid monomethylamide
• 英文别名: 5-(methylamino)-5-oxoPentanoic acid
• CAS: 105611-99-2
• 化学式: C₆H₁₁NO₃
• 分子量: 145.158
• InChiKey: RUDZEQGATNKWHM-UHFFFAOYSA-N

物化性质

• 熔点：
  196-196.5 °C
• 沸点：
  401.5±28.0 °C(Predicted)
• 密度：
  1.132±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 戊酸,5-(甲基氨基)-5-羰基- 在 硫酸 作用下， 以 水 为溶剂， 生成 N-methylglutaramide methyl ester
  参考文献：
  名称：

  Conformation-directing effects of a single intramolecular amide-amide hydrogen bond: variable-temperature NMR and IR studies on a homologous diamide series

  摘要：

  We have studied intramolecular hydrogen bonding in a homologous series of diamides (compounds 1-6) in methylene chloride, 9:1 carbon tetrachloride/benzene, and acetonitrile. By correlating variable-temperature H-1 NMR and IR measurements, we have shown that the temperature dependence of the amide proton NMR chemical shift (DELTA-delta/DELTA-T) can provide qualitative (and in some cases quantitative) information on the thermodynamic relationship between the intramolecularly hydrogen bonded and non-hydrogen-bonded states of flexible molecules. Among the hydrogen-bonded ring sizes represented in the diamide series, the intramolecular interaction is particularly enthalpically favorable in the nine-membered hydrogen-bonded ring (compound 4). Variable-temperature IR and NMR data indicate that the internally hydrogen bonded state of diamide 4 is 1.4-1.6 kcal/mol more favorable enthalpically than the non-hydrogen-bonded state, in methylene chloride solution; the non-hydrogen-bonded state is 6.8-8.3 eu more favorable entropically in this solvent. In contrast, there appear to be much smaller enthalpy differences between the internally hydrogen bonded and non-hydrogen-bonded states of diamides 2 and 3. Our findings are important methodologically because the temperature dependences of amide proton chemical shifts are commonly used to elucidate peptide conformation in solution. Our results show that previous "rules" for the interpretation of such data are incomplete. In non-hydrogen-bonding solvents, small amide proton DELTA-delta/DELTA-T values have been taken to mean that the proton is either entirely free of hydrogen bonding or completely locked in an intramolecular hydrogen bond over the temperature range studied. We demonstrate that an amide proton can be equilibrating between intramolecularly hydrogen bonded and non-hydrogen-bonded states and still manifest a small chemical shift temperature dependence (implying that the hydrogen-bonded and non-hydrogen-bonded states are of similar enthalpy).

  DOI：

  10.1021/ja00004a016
• 作为产物：
  描述：

  1-(2-chloroethyl)-3-methyl-3-(4-carboxybutanoyl)triazene 在 phosphate buffer 、 sodium chloride 作用下， 生成 戊酸,5-(甲基氨基)-5-羰基- 、 2-氯乙醇
  参考文献：
  名称：

  1-（2-氯乙基）-3-烷基-3-酰基三氮烯对DNA烷基化的特异性取决于酰基的结构：动力学和产物研究。

  摘要：

  单独研究了小牛胸腺DNA与十个具有不同酰基侧链结构的1-（2-氯乙基）-3-烷基-3-酰基苯甲酰氮的反应，或在pH 7.0磷酸盐缓冲液中在猪肝酯酶存在下的反应。在几种关键的三氮烯中，酰基取代基包含一个游离的羧酸基团。在反应混合物中存在酯酶的情况下，所得的DNA烷基化水平可能与三氮烯分解的动力学速率相关。在这些条件下，主要的分解途径涉及母体三氮烯的脱酰作用并最终产生链烷重氮离子。该中间体随后将DNA-鸟嘌呤烷基化，得到7-烷基鸟嘌呤作为主要反应产物。在没有酯酶的情况下，DNA烷基化的顺序对所有的acyltriazenes都不与它们各自的分解速率相关，从而得出结论，三氮烯不会被未催化的N（2）-N（3）杂多裂解的预期模式分解。N（3）-甲基三氮烯的主要DNA烷基化产物是7-甲基鸟嘌呤，而不是预期的7-（氯乙基）-和7-（羟乙基）鸟嘌呤，这表明酰基正在被水解。但是，与预测相反，在该位置具有N（3

  DOI：

  10.1021/tx950155y

文献信息

• [EN] COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS ET PROCÉDÉS DESTINÉS À INHIBER UN ANTIPORT MÉDIÉ PAR NHE DANS LE TRAITEMENT DES TROUBLES ASSOCIÉS À UNE RÉTENTION DE FLUIDE OU À UNE SURCHARGE DE SEL ET DES TROUBLES DU TRACTUS GASTRO-INTESTINAL
  申请人：ARDELYX INC

  公开号：WO2014029984A1

  公开（公告）日：2014-02-27

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗与液体潴留或盐过多有关的疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾病、晚期肾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• Novel peptides which are active on the central nervous system and have
  申请人：Hoechst Aktiengeselleschaft

  公开号：US04623715A1

  公开（公告）日：1986-11-18

  The invention relates to peptides of the formula I R.sup.4 --A.sup.5 --A.sup.6 --A.sup.7 (I) in which R.sup.4 denotes an acyl group, R.sup.5 denotes D-Lys or Lys, A.sup.6 denotes the radical of phenylalanine, N-methylphenylalanine, 4- alkoxyphenylalanine or 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, and R.sup.7 denotes a basic radical, processes for their preparation and their use.

  本发明涉及公式I中的肽，其中R.sup.4表示酰基基团，R.sup.5表示D-Lys或Lys，A.sup.6表示苯丙氨酸、N-甲基苯丙氨酸、4-烷氧基苯丙氨酸或1,2,3,4-四氢异喹啉-3-羧酸的基团，R.sup.7表示碱性基团，以及其制备方法和用途。
• NOVEL FLUORESCENT DYES AND USES THEREOF
  申请人：Ramage Robert

  公开号：US20090226940A1

  公开（公告）日：2009-09-10

  The present invention relates to fluorescent dyes based on acridine derivatives and use of such dyes, for example, in biochemical and/or cell based assays. A preferred feature of some of the dyes described is their long fluorescence lifetimes and their use to label biological molecules.

  本发明涉及基于吖啶衍生物的荧光染料及其在生化和/或细胞基础测定中的应用。所述染料的首选特征是其长荧光寿命和其用于标记生物分子的应用。
• Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Honda Takahiro

  公开号：US20070149574A1

  公开（公告）日：2007-06-28

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R 1 and R 2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R 3 and R 4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R 5 , etc.; R 5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR 6 —, —SO 2 —, etc.; R 6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种具有4-吡啶基烷基硫基团的新型环状化合物，其中引入了（未）取代氨基或其盐。它们可用作药物。环状化合物是由以下式（1）表示的化合物，可用于治疗参与血管生成的疾病。在下式（1）中，环A表示苯环或5-或6-成员芳香杂环，可选择地与环烷环融合；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示-CO-，-COO-，-CONR6-，-SO2-等；R6表示H等；p为0、1或2；q为0或1。
• Nitrogen-containing 5-membered ring compound
  申请人：Yasuda Kosuke

  公开号：US20080153821A1

  公开（公告）日：2008-06-26

  The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein symbols in the formula have the following meanings; A: —CH 2 — or —S—, B: CH or N, R 1 : H, a lower alkyl group, etc., X: a single bonding arm, —CO—, -Alk-CO—, —COCH 2 —, -Alk-O—, —O—CH 2 —, —SO 2 —, —S—, —COO—, —CON(R 3 )—, -Alk-CON(R 3 )—, —CON(R 3 )CH 2 —, —NHCH 2 —, etc., R 3 : hydrogen atom or a lower alkyl group, Alk: a lower alkylene group, and R 2 : (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is —CO—, then B is N, or a pharmaceutically acceptable salt thereof.

  本发明提供一种由式[I]表示的脂肪族氮含有5元环化合物，其中式中符号的含义如下：A：—CH2—或—S—，B：CH或N，R1：H、低碳基等，X：一个单键臂、—CO—、-Alk-CO—、—COCH2—、-Alk-O—、—O—CH2—、—SO2—、—S—、—COO—、—CON(R3)—、-Alk-CON(R3)—、—CON(R3)CH2—、—NHCH2—等，R3：氢原子或低碳基，Alk：低碳亚烷基，以及R2：（1）一个可能被取代的环状基团，（2）一个取代的氨基团等，前提是当X为—CO—时，B为N，或其药学上可接受的盐。